Radiopharmaceuticals

Radionuclides, radiopharmaceuticals, and product labeling kits must be either procured from an NRC or Agreement State licensed radiopharmaceutical vendor or proposal by a nuclear pharmacist or physician authorized user, and meet appropriate standards of purity and sterility.  Kits must be prepared and used in accordance with approved instructions furnished by the manufacturer and accompanying each reagent kit. Records of use of unit and multi-dose will be kept as specified in Appendix F. For Tc-99m doses, the Nuclear Medicine Technologist will either perform a Moly breakthrough test as per Appendix P or review the results of the Moly breakthrough assay performed by the supplier of the radiopharmaceutical. No dose will be used when, at the time of administration, there is more than 0.15 microcurie of Mo 99 per millicurie of Tc 99m.  For all gamma emitting doses whose prescribed activity is > 10 uCi, the dose shall be assayed in the dose calibrator to an accuracy of + 10% prior to being administered to patients. No dose > 10 uCi shall be administered to a patient if it exceeds the  prescribed activity by + 10%.

Misadministrations

Potential misadministrations should be reported immediately and investigated by the RSO. Misadministrations as defined in 902 KAR 100 regulations, should be reported as per applicable sections of that document.

Radiation Detection Equipment

Calibration and quality control of equipment utilized to measure, detect and assay radioactive material will be performed as per Appendix G.